Annual ROE
-187.61%
-72.65%-63.20%
December 31, 2023
Summary
- As of February 7, 2025, ADAP annual return on equity is -187.61%, with the most recent change of -72.65% (-63.20%) on December 31, 2023.
- During the last 3 years, ADAP annual ROE has fallen by -131.64% (-235.20%).
- ADAP annual ROE is now -147.78% below its all-time high of 392.67%, reached on June 30, 2013.
Performance
ADAP ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-67.80%
+28.88%+29.87%
September 30, 2024
Summary
- As of February 7, 2025, ADAP quarterly return on equity is -67.80%, with the most recent change of +28.88% (+29.87%) on September 30, 2024.
- Over the past year, ADAP quarterly ROE has increased by +157.57% (+69.92%).
- ADAP quarterly ROE is now -3841.86% below its all-time high of -1.72%, reached on September 30, 2015.
Performance
ADAP Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
ADAP ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -63.2% | +69.9% |
| 3 y3 years | -235.2% | -34.5% |
| 5 y5 years | -341.9% | -1.5% |
ADAP ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -224.7% | at low | -17.9% | +69.9% |
| 5 y | 5-year | -235.2% | at low | -57.3% | +69.9% |
| alltime | all time | -147.8% | +97.9% | -3841.9% | +69.9% |
Adaptimmune Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -67.80%(-29.9%) |
| Jun 2024 | - | -96.68%(-57.1%) |
| Mar 2024 | - | -225.37%(+66.3%) |
| Dec 2023 | -187.61%(+63.2%) | -135.55%(+40.6%) |
| Sep 2023 | - | -96.39%(+16.0%) |
| Jun 2023 | - | -83.10%(-15.0%) |
| Mar 2023 | - | -97.71%(-16.6%) |
| Dec 2022 | -114.96%(+99.0%) | -117.14%(+15.8%) |
| Sep 2022 | - | -101.15%(+18.4%) |
| Jun 2022 | - | -85.46%(+19.9%) |
| Mar 2022 | - | -71.25%(+24.0%) |
| Dec 2021 | -57.78%(+3.2%) | -57.48%(+14.0%) |
| Sep 2021 | - | -50.42%(+16.0%) |
| Jun 2021 | - | -43.48%(+0.9%) |
| Mar 2021 | - | -43.11%(-4.9%) |
| Dec 2020 | -55.97%(-24.4%) | -45.34%(-8.4%) |
| Sep 2020 | - | -49.49%(-17.8%) |
| Jun 2020 | - | -60.23%(-24.5%) |
| Mar 2020 | - | -79.81%(+7.6%) |
| Dec 2019 | -74.04% | -74.16%(+11.0%) |
| Sep 2019 | - | -66.82%(+47.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2019 | - | -45.41%(-2.3%) |
| Mar 2019 | - | -46.49%(+5.0%) |
| Dec 2018 | -42.46%(+11.7%) | -44.28%(+8.4%) |
| Sep 2018 | - | -40.84%(-10.7%) |
| Jun 2018 | - | -45.72%(+39.7%) |
| Mar 2018 | - | -32.72%(-3.3%) |
| Dec 2017 | -38.00%(+6.5%) | -33.85%(+17.7%) |
| Sep 2017 | - | -28.77%(-25.6%) |
| Jun 2017 | - | -38.69%(-3.5%) |
| Mar 2017 | - | -40.08%(+13.4%) |
| Dec 2016 | -35.69%(+283.4%) | -35.34%(+15.3%) |
| Sep 2016 | - | -30.65%(+14.8%) |
| Jun 2016 | - | -26.69%(+72.6%) |
| Mar 2016 | - | -15.46%(+798.8%) |
| Dec 2015 | -9.31%(-44.8%) | - |
| Sep 2015 | - | -1.72%(-83.3%) |
| Jun 2015 | -16.88%(-99.8%) | - |
| Dec 2014 | - | -10.31%(-92.4%) |
| Sep 2014 | - | -135.52% |
| Jun 2014 | -9122.11%(-2423.1%) | - |
| Jun 2013 | 392.67% | - |
FAQ
- What is Adaptimmune Therapeutics annual return on equity?
- What is the all time high annual ROE for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual ROE year-on-year change?
- What is Adaptimmune Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly ROE year-on-year change?
What is Adaptimmune Therapeutics annual return on equity?
The current annual ROE of ADAP is -187.61%
What is the all time high annual ROE for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual return on equity is 392.67%
What is Adaptimmune Therapeutics annual ROE year-on-year change?
Over the past year, ADAP annual return on equity has changed by -72.65% (-63.20%)
What is Adaptimmune Therapeutics quarterly return on equity?
The current quarterly ROE of ADAP is -67.80%
What is the all time high quarterly ROE for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly return on equity is -1.72%
What is Adaptimmune Therapeutics quarterly ROE year-on-year change?
Over the past year, ADAP quarterly return on equity has changed by +157.57% (+69.92%)